Bone graft, held to a higher standard.
The biologics behind the fusion, from allograft and synthetics to the patient’s own MSCs.
Allograft, synthetic, marrow. Every case covered.
Allograft
Cortical fiber, DBM putty and cancellous bone in moldable, flowable and strip forms.
- PURbonedough
- PURfiberXP
- PURindux
- PURfuze
- PURfuzePlus
- PURflex
- PURchips
Synthetic
Bioactive glass, bioceramic and collagen matrices in putty, strip and granule form.
- PURactiveOrb
- PURbridge
- PURcrystals
- PURpillars
MSC recovery
A focused system for recovering the patient’s own marrow-derived MSCs at the point of care.
- PURmarrow360
Where fusion goes next.
Much of what goes into a fusion today was designed a generation ago. The biology has moved on. PUR is building the next generation on how bone actually heals: engineered bioactive surfaces, carrier-free bone and the patient’s own cells, brought together as one platform. Behind every one of those decisions is a patient, and a surgeon who answers to them. That is who the work is for, and that is the scale it has to meet.
PURactiveOrb™
Bioactive glass in orbital form. PURactiveOrb packs bioactive glass into engineered orbs of two sizes, about 80% glass by weight, in a moldable, non-hardening phospholipid putty. The orbs pack densely, present a large bioactive surface for cellular attachment, and leave open spaces between them for new bone to grow into.
PURbonedough™
PURbonedough is 100% human cortical bone, cut into short fibers that interlock when you hydrate them into a dough that holds together, packs where you put it and stays put under irrigation. Nothing in the jar but bone, and every lot tested for osteoinductive potential before it ships.
Bone graft has had a standard for decades. We’re here to raise it.
Accreditation and sterility assurance are where every tissue supplier starts. The PUR standard is what we hold ourselves to beyond that: technology that advances the biology, evidence on every lot, and a pipeline aimed at what fusion should look like ten years from now.
- Technology first
Orbital bioactive glass, carrier-free cortical fibers, materials designed around how cells attach and grow. We build for the biology first.
- Evidence on every lot
Every DBM lot is tested for osteoinductive potential before release. We don’t sample what we can test.
- Pipeline, not just portfolio
Twelve products today, and a development program aimed at what comes after them. The portfolio is where we are, not where we stop.
- People over product
Twenty years beside surgeons taught us that a graft is judged by the patient, not the catalog. Every decision traces to that, at the scale of everyone who needs one.
Twelve products. One standard.
Your graft. Your approach.
PURactiveOrb is available with a minimally invasive delivery option: a trigger-fed instrument and cannula that place putty through a small access corridor.
Focused on biologics. Built around surgeons.
PUR Biologics is a commercial-stage orthobiologics company based in Irvine, California. For thirteen years we have brought allograft, synthetic graft and MSC-recovery products to spine and orthopedic surgeons through a focused portfolio and direct relationships with the people who use it.
We work with surgeons, hospitals and surgery centers, and distribution partners across the United States.
Bone was the first frontier. It won’t be the last.
A 510(k)-cleared platform of porous HA/TCP spheres in a mesh carrier, evaluated head-to-head against leading grafts in a large-animal model, now moving through manufacturing transfer.
A patented second-generation, iPSC-derived process for scalable, collagen-rich ECM, building on a first generation that regenerated integrated hyaline cartilage in large-animal models. First targets: cartilage repair and osteoarthritis.
Two issued patents on a defined chemistry that activates bone-marrow-derived immune cells, with bone regeneration first and a reach that extends beyond orthopedics.
Talk to the people behind the portfolio.
Product literature, current instructions for use, ordering, or a conversation about distribution. Our team answers directly.
Purpose in every form.
Twelve products across three families: allograft, synthetics and MSC recovery.
Need product literature or the current IFU?
PURactiveOrb™
Bioactive glass in orbital form. Engineered orbs of two sizes, about 80% glass by weight, in a resorbable phospholipid carrier: moldable, non-hardening, resists irrigation, and ready through a 9 mm cannula.
Engineered down to the orb.
A material with history. A form without compromise.
Bioactive glass is among the most studied synthetic graft materials in orthopedics. Conventional putties use it as crushed, irregular particles. PURactiveOrb uses orbs: two engineered diameters, 90–180 µm and 355–500 µm, blended in a fixed ratio. The smaller orbs fill the spaces between the larger ones, so the putty packs more glass into the defect and presents a consistent, high surface area to surrounding bone, with interconnected spaces between the orbs for cells and vessels to move into.
That surface is where the material does its work. Bioactive glass forms a calcium phosphate layer at its surface after implantation, and in the orbital form every orb presents that surface for cellular attachment. The result is a putty that is about 80% bioactive glass by weight, roughly 1.5 grams of glass in every cc, bound by a natural phospholipid carrier. After placement the carrier is resorbed and the glass remains in direct contact with host bone.
In a preclinical rabbit defect model, new bone formed directly on the orb surfaces and in the spaces between them, with bone present throughout the implant area at six weeks.1
Supplied in an open-bore syringe sealed within two foil pouches, in 2.5, 5 and 10 cc volumes. No hydration step.
- MoldableShape it in your fingers, contour it to the defect, place it.
- Non-hardeningStays workable and does not set in situ. Not intended to provide structural support.
- Resists irrigationStays where you put it under irrigation, as described in the instructions for use.
- Ready when you areOpen-bore syringe, double foil pouch, single patient use. Open it and go.
1 Preclinical animal study, data on file. Results in animal models do not necessarily predict clinical performance in humans.
Your graft. Your approach.
A trigger-fed instrument and cannula place PURactiveOrb through a minimally invasive corridor in controlled increments.
Indications & safety.
Intended use
PURactiveOrb Putty is indicated for bony voids or gaps that are not intrinsic to the stability of the bony structure. It is indicated as a bone void filler in the extremities and pelvis, and as a bone graft extender in the posterolateral spine.
For posterolateral fusion, PURactiveOrb Putty must be mixed with autograft in a 1:1 ratio.
This summary does not replace the complete instructions for use, including contraindications, warnings, precautions and directions.
Handling
Do not add fluid directly to the putty, including blood or saline. This may negatively affect handling and cohesiveness. Refer to the current IFU for preparation and use.
Structural support and single use
The product does not possess sufficient mechanical strength to solely support defect reduction. Appropriate stabilization is required. The product is for single-patient, single use only.
PURbonedough™
100% human cortical bone in a dough that holds together, packs where you put it and stays put under irrigation. Nothing in the jar but bone.
Bone, and only bone.
Cortical fibers that interlock
PURbonedough is made from 100% human cortical bone, processed into short fibers. There is no extrinsic carrier: no collagen, no gelatin, no synthetic binder. When the fibers are hydrated they interlock into a cohesive dough, so the graft handles like a putty while every gram of it is bone.
Supplied dry in a jar, stored at room temperature, with a five-year shelf life from the date of packaging.
- 100% cortical boneNo carrier of any kind. What you place is bone matrix and nothing else.
- Dough handlingPacks into the defect, holds its shape and stays put under irrigation.
- Room temperatureNo cold chain. Shelf life of five years from packaging.
- 1 to 10 ccFour jar sizes for everything from a small void to a multilevel posterolateral bed.
Hydrate it your way.
PURbonedough is hydrated in the field with the fluid the surgeon chooses: saline, whole blood, bone marrow aspirate or platelet-rich plasma, at the physician’s discretion. The fibers take up the fluid and bind into a dough that can be shaped, packed and held in place.
Osteoinductive potential, verified lot by lot.
Demineralized bone is only as good as the lot in your hand. Every lot of PURbonedough is tested for osteoinductive potential by an independent laboratory after sterilization and before release. Not sampled. Not inferred from a sister lot. Tested.
Indications & safety.
Intended use
PURbonedough is a human tissue allograft intended for homologous use in the repair, replacement or reconstruction of surgically created or traumatic skeletal defects.
This summary does not replace the complete instructions for use, including contraindications, warnings, precautions and directions. Human tissue is regulated under 21 CFR Part 1271.
Handling and hydration
Hydrate per the instructions for use with the fluid selected by the physician. Do not re-sterilize. Single patient, single use.
Storage
Store at ambient temperature, 15–30 °C (59–86 °F). Do not use after the expiration date on the label.
Bone was the first frontier. It won’t be the last.
PUR holds a cleared next-generation bone graft platform, an issued patent estate in extracellular matrix and cell activation, and a matrix technology with large-animal cartilage regeneration in its lineage. One biology, applied in sequence: bone today, cartilage and osteoarthritis next.
Four programs. One direction.
Stages reflect the furthest point reached by each program. Preclinical results do not predict clinical outcomes; programs beyond the commercial portfolio are not available for sale.
A graft designed as an incubator.
Most synthetic grafts are a material to fill a space. This platform is engineered as an environment. Each porous hydroxyapatite/tricalcium phosphate sphere is a micro-architecture for cells to migrate into, attach to and signal across, and the mesh carrier holds that architecture exactly where the fusion needs it.
The platform is 510(k)-cleared for posterolateral spine graft extension and has been evaluated head-to-head against leading commercial grafts in a large-animal defect model.1 Manufacturing transfer and shelf-life studies are the remaining steps to commercial release.
1 Preclinical data. Animal results do not necessarily predict clinical performance. This platform is distinct from PURactiveOrb Putty, our bioactive glass product.
Manufacturing the scaffold every tissue is built on.
Extracellular matrix is the structure living tissue is built on. It tells cells where to anchor, when to divide and what to become. PUR’s issued patent covers a way to manufacture it at scale: fibroblasts derived from induced pluripotent stem cells, grown in bioreactors, producing a nano-structured, collagen-rich matrix along with the growth factors and proteins that come with it.
The first generation of this matrix produced integrated hyaline cartilage, new vascular supply and a marked anti-inflammatory response in large-animal models.2 PUR has since divested that generation and patented a second: the same biology, re-engineered in the manufacturing process and the matrix itself with the aim of improving on those results. The first targets are cartilage repair and osteoarthritis, where the current options end at pain relief and joint replacement.
- Issued patentMethod and formulation of ECM for cartilage regeneration and osteoarthritis
- Scalable by designiPSC-derived cell lines in bioreactors, not donor-limited tissue
- Proven lineageFirst-generation matrix regenerated integrated hyaline cartilage in large-animal models2
- Second generationPatented improvements to the process and the matrix, designed to build on the first-generation results
2 Preclinical data from a first-generation matrix technology no longer owned by PUR. The current, second-generation matrix has not yet been evaluated in those models; its design objectives are not established results. Not available for sale; not cleared or approved for any indication.
Instructing the body’s own cells to rebuild.
Bone marrow carries the immune cells that orchestrate healing. PUR holds issued patents on both a device and a method for activating them: a defined blend of molecules that primes bone-marrow-derived immune cells precisely and efficiently, with bone regeneration as the first application.
The mechanism is not specific to bone. A platform that can reliably activate a patient’s own immune cells has a reach that extends well beyond orthopedics.
Three issued patents. A foundation that compounds.
PUR’s patent estate spans extracellular matrix manufacturing and immune-cell activation, with ownership of the sphere platform’s 510(k)s and exclusive licenses on its core technologies. Each program draws on the others: the matrix feeds the cartilage work, the activation chemistry feeds the bone work, and the commercial portfolio funds all of it.